CBFP
AZN icon

Cedar Brook Financial Partners’s AstraZeneca AZN Stock Holding History

Cedar Brook Financial Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,385
Closed -$216K – 9
2024
Q2 		$216K Sell
1,385
-4,823
-78% -$726K 1.63% 23
2024
Q1 		$841K Sell
6,208
-28
-0.4% -$3.71K 0.17% 144
2023
Q4 		$863K Sell
6,236
-315
-5% -$40.9K 0.19% 126
2023
Q3 		$887K Buy
6,551
+48
+0.7% +$6.56K 0.23% 104
2023
Q2 		$931K Sell
6,503
-298
-4% -$43.8K 0.22% 110
2023
Q1 		$944K Buy
6,801
+176
+3% +$23.7K 0.24% 104
2022
Q4 		$898K Buy
6,625
+629
+10% +$78.9K 0.25% 108
2022
Q3 		$658K Buy
5,996
+516
+9% +$65.5K 0.21% 123
2022
Q2 		$724K Sell
5,480
-281
-5% -$36.9K 0.23% 112
2022
Q1 		$764K Buy
5,761
+154
+3% +$18.5K 0.2% 130
2021
Q4 		$653K Buy
5,607
+173
+3% +$20.4K 0.17% 147
2021
Q3 		$653K Buy
5,434
+335
+7% +$39K 0.2% 127
2021
Q2 		$611K Buy
5,099
+398
+8% +$43.7K 0.18% 145
2021
Q1 		$467K Buy
4,701
+606
+15% +$60.9K 0.16% 151
2020
Q4 		$409K Buy
4,095
+517
+14% +$54.8K 0.14% 168
2020
Q3 		$392K Buy
3,578
+56
+2% +$6.23K 0.15% 168
2020
Q2 		$373K Sell
3,522
-72
-2% -$7.44K 0.17% 162
2020
Q1 		$321K Sell
3,594
-218
-6% -$20.5K 0.18% 161
2019
Q4 		$380K Sell
3,812
-81
-2% -$7.63K 0.16% 171
2019
Q3 		$347K Buy
3,893
+435
+13% +$37.7K 0.15% 189
2019
Q2 		$285K Buy
3,458
+129
+4% +$10.1K 0.13% 214
2019
Q1 		$269K Buy
+3,329
New +$262K 0.13% 214

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cedar Brook Financial Partners's AZN Position: Q3 2024 in Review

Cedar Brook Financial Partners sold out of AstraZeneca (AZN) in Q3 2024, closing a stake of 1,385 shares — an estimated $216K sold.

Cedar Brook Financial Partners first reported a position in AZN in Q1 2019 and held it in 22 quarters. The position peaked at $944K in Q1 2023. 1,229 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

  • Cedar Brook Financial Partners reported no remaining AstraZeneca position as of Q3 2024 after selling out during the quarter.
  • Cedar Brook Financial Partners sold 1,385 AstraZeneca shares in Q3 2024, an estimated $216K.
  • Cedar Brook Financial Partners first reported a position in AstraZeneca in Q1 2019 and held it in 22 quarters.
  • Cedar Brook Financial Partners's AstraZeneca position peaked at $944K in Q1 2023.
  • 1,229 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on Cedar Brook Financial Partners's 13F filing for Q3 2024, filed 21 Oct 2024.